Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$1.15MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Allan Reine
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 146
- Beta
- 2.35
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -6.12
Financials
Revenue
$1.15M+95.3%Net Income
$-42.11MEBITDA
$-40.32MFree Cash Flow
$-41.09MEPS (diluted)
$-0.24Shares Outstanding (diluted)
177.22M+85.1%Operating Expenses
$44.44MCash & Debt
$95.07MRevenue by Segment (annual)
$4.63MDividend per Share
$0.01Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.63M | $-201.14M | $-1.35 |
| 2024 | $2.98M | $-195.88M | $-1.65 |
| 2023 | $0.00 | $-198.13M | $-2.18 |
| 2022 | $0.00 | $-121.82M | $-1.46 |
| 2021 | $0.00 | $-165.37M | $-1.92 |
| 2020 | $5.21M | $-3.41M | $-0.05 |
| 2019 | $0.00 | $-2.53M | $-0.03 |
Valuation
PRMEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
87-27.78%Social Signal Score
Mentions (6)
- Newsbenzinga.com·10d ago·Negative
Prime Medicine Gets FDA Green Light for Gene Editing Study Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology firm developing one-time curative genetic therapies, announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for PM647.
View source ↗ - Newsglobenewswire.com·11d ago·Negative
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency -- Clearance highlights continued execution, modularity and momentum across Prime Medicine's liver franchise, building on recent regulatory clearances for PM577a -- -- Initial clinical data expected in 2027 --
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Prime Medicine, Inc. (PRME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Prime Drink Group Provides Bi-Weekly MCTO Status Report MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14 and August 27, 2026, the Company voluntarily applied for and the Company's principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Ce…
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Prime Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.
View source ↗ - Newsseekingalpha.com·51d ago·Positive
Prime Medicine: Soon In The Clinic Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immunology/oncology, with leading preclinical efficacy and multi-billion-dollar addressable markets. Recent IND/CTA clearances, RMAT designation, and patent wins highlight PRME's clinical and strategic momentum despite a 54% stock decline from 52-week highs.
View source ↗
Earnings
Fri, Nov 6(in 4 weeks)
Consensus estimate $-0.24 per share
Typical surprise -13.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.24 vs $-0.26beat
- Thu, May 7$-0.28 vs $-0.24miss
- Tue, Mar 3$-0.22 vs $-0.25beat
- Fri, Nov 7$-0.32 vs $-0.28miss
- Thu, Aug 7$-0.41 vs $-0.36miss
- Thu, May 8$-0.40 vs $-0.32miss
Estimates and results for PRME via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PRME officers and directors.
- Bought
- $35.4m
- Sold
- —
11 trades
0 trades
- Gv 2021 Gp, L.l.c.bought
- Nelsen Robertbought
- Arch Venture Partners Xii, Llcbought
- Arch Venture Partners X, Llcbought
- Liu David R.bought
- Liu David R.bought
- Liu David R.bought
- Liu David R.bought
89 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PRME.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.